Subscribe Become an Author Add Company Sign Up Log In

Standigm

Standigm

Private company
STANDIGM

Standigm applies cutting-edge AI technologies to drug discovery. AI and biology experts team up to build a real-world AI model for the pharmaceutical industry. We currently focus on predicting new indications for existing drugs, called drug repositioning through the deeply trained AI model with molecular features of drug responses and drug uses. Standigm generated tens of drug candidates for cancers, Parkinson’s disease (PD), autism, fatty liver diseases (NASH) and more. We promise practical benefits on time and cost in pharmaceutical industry by eliminating some of the uncertainty in the drug discovery process.


Founded
2015
Status
Private company
Geography
South Korea based
Funding
$15.190 M
Patents
1
Product type
  • Small molecules
Research focus
  • Biology research (Target identification/validation)
  • Drug Repurposing
  • Lead Discovery
  • Preclinical Development

Investing history

2019Series B11.5
2016Seed round0.25
2016Series A3.0
2015Seed round0.44

Press releases

    No mentions found

Posts Mentioning This Company

Biopharma Insights

Products

No products posted yet

Services

No services posted yet

Clinical Trials

    No clinical trials found

Patents/applications

    No patents found

Publications (PubMed)

    No publications found

Assets (therapeutic products)

    No assets found

Year Partner Focus Amount of Deal
2017

(2017, Jan. 1)
CrystalGenomics discover and develop novel drugs in the therapeutic area of cancer, rheumatoid arthritis and liver related diseases. --